A new era of MRD detection begins
Spotlight the signal with the next-generation Oncodetect MRD test
What is molecular residual disease?
Molecular residual disease (MRD) can be shed by cancer cells into the bloodstream in the form of tumor-specific DNA, also called circulating tumor DNA or ctDNA. This can happen during or after cancer treatment.
- The presence of ctDNA may indicate that cancer is present in the body, even when not detected by current standard of care methods.
2 - ctDNA contains unique variants that can be detected by highly sensitive tests, offering real-time measurement of the disease burden.
3 - The detection and monitoring of MRD can help inform treatment decisions.
4
Detect cancer early to inform treatment decisions
The next-generation Oncodetect test looks for minute signs of cancer related to a specific tumor. This kind of MRD testing allows you to detect cancer recurrence or progression earlier than with current standard methods,
Earlier detection and monitoring can help patients and providers:
- Determine whether any cancer is detectable post-surgery, or if further treatment is necessary.
1 - Assess whether the cancer is likely to come back.
1 - Learn how cancer is responding to treatment.
1
Innovation you can trust
We’re dedicated to helping patients and providers make the most informed decisions in cancer prevention, treatment, and monitoring, by harnessing the latest innovations in screening and detection.
With more than 20 years of experience in genomic oncology, we’ve empowered over 2 million patients
With the Oncodetect test, you get highly sensitive ctDNA detection,
The limit of detection of the next-generation Oncodetect test is 30x lower than our first-generation test.6,7
With an ultra-low limit of detection, the next-generation Oncodetect test provides residual disease detection and monitoring, allowing you to make more informed treatment decisions.
Outstanding sensitivity, high specificity.6
By tracking up to 5,000 variants specific to a patient’s tumor, the next-generation Oncodetect MRD test grants more opportunities to detect ctDNA in the blood compared to the first-generation test.
The next-generation Oncodetect test tracks up to 5,000 tumor-specific variants, leveraging broad coverage to achieve an ultra-low limit of detection.
The next-generation Oncodetect test can enrich tumor DNA up to 1000x, making ultra-rare mutations easy to detect with greater confidence compared to the first-generation Oncodetect test.
An ultra-low limit of detection provides confidence when every molecular signal counts.
*Under high-end inputs.